This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Odunsi, K. Articles by Old, L. J. Search for Related Content PubMed PubMed Citation Articles by Odunsi, K. Articles by Old, L. J.

NY-ESO-1 and LAGE-1 Cancer-Testis Antigens Are Potential Targets for Immunotherapy in Epithelial Ovarian Cancer¹

Divisions of Gynecologic Oncology [K. O., F. Q., J. T., B. K., S. L.], Pathology [M. I., A. B.], Biostatistics [D. D.], and Immunology [K. O., F. Q., A. S.], Roswell Park Cancer Institute, Buffalo, New York 14263; Weill Medical College of Cornell University, New York, New York 10021 [Y-T. C.]; Ludwig Institute for Cancer Research, New York Branch at Memorial Sloan-Kettering Cancer Center, New York, New York 10021 [A. J., E. S., S. G., D. S., B. W., M. J. S., G. R., L. J. O.]

Cancer-testis (CT) antigens are expressed in a variety of cancers, but not in normal adult tissues, except for germ cells of the testis, and hence appear to be ideal targets for immunotherapy. In an effort to examine the potential of NY-ESO-1 and LAGE-1 CT antigens for immunotherapy in epithelial ovarian cancer (EOC), we examined the expression of these antigens by reverse transcription-PCR (RT-PCR) and immunohistochemistry (IHC) in a large panel of EOC tissues and cell lines. Sera from a subgroup of the patients were tested for NY-ESO-1/LAGE-1 antibody by ELISA. The data indicated that four ovarian cancer cell lines were positive for one or both CT antigens. Expression of NY-ESO-1 in EOC was demonstrated by RT-PCR and/or IHC in 82 of 190 (43%) specimens. NY-ESO-1 expression by IHC ranged from homogeneous to heterogeneous pattern. LAGE-1 mRNA expression was present in 22 of 107 (21%) tumor tissues. Overall, the expression of either NY-ESO-1 or LAGE-1 mRNA was present in 42 of 107 (40%) EOC specimens and coexpression of both antigens was demonstrated in 11% of specimens. Antibody to NY-ESO-1/LAGE-1 was present in 11 of 37 (30%) patients whose tumors expressed either NY-ESO-1 or LAGE-1. Detectable antibodies were present for up to 3 years after initial diagnosis. Although there was no statistically significant relation between expression of NY-ESO-1/LAGE-1 antigen and survival, the data showed aberrant expression of NY-ESO-1 and LAGE-1 by IHC/RT-PCR in a significant proportion of EOC patients. These findings indicate that NY-ESO-1 and LAGE-1 are attractive targets for antigen-specific immunotherapy in EOC.

This article has been cited by other articles:

				J. RIES, N. MOLLAOGLU, E. VAIRAKTARIS, F. W. NEUKAM, and E. NKENKE Diagnostic and Therapeutic Relevance of NY-ESO-1 Expression in Oral Squamous Cell Carcinoma Anticancer Res, December 1, 2009; 29(12): 5125 - 5130. [Abstract] [Full Text] [PDF]

				Y. Nesbeth, U. Scarlett, J. Cubillos-Ruiz, D. Martinez, X. Engle, M.-J. Turk, and J. R. Conejo-Garcia CCL5-Mediated Endogenous Antitumor Immunity Elicited by Adoptively Transferred Lymphocytes and Dendritic Cell Depletion Cancer Res., August 1, 2009; 69(15): 6331 - 6338. [Abstract] [Full Text] [PDF]

				E. Huarte, J. R. Cubillos-Ruiz, Y. C. Nesbeth, U. K. Scarlett, D. G. Martinez, R. J. Buckanovich, F. Benencia, R. V. Stan, T. Keler, P. Sarobe, et al. Depletion of Dendritic Cells Delays Ovarian Cancer Progression by Boosting Antitumor Immunity Cancer Res., September 15, 2008; 68(18): 7684 - 7691. [Abstract] [Full Text] [PDF]

				A. Woloszynska-Read, P. Mhawech-Fauceglia, J. Yu, K. Odunsi, and A. R. Karpf Intertumor and Intratumor NY-ESO-1 Expression Heterogeneity Is Associated with Promoter-Specific and Global DNA Methylation Status in Ovarian Cancer Clin. Cancer Res., June 1, 2008; 14(11): 3283 - 3290. [Abstract] [Full Text] [PDF]

				C. S.M. Diefenbach, S. Gnjatic, P. Sabbatini, C. Aghajanian, M. L. Hensley, D. R. Spriggs, A. Iasonos, H. Lee, B. Dupont, S. Pezzulli, et al. Safety and Immunogenicity Study of NY-ESO-1b Peptide and Montanide ISA-51 Vaccination of Patients with Epithelial Ovarian Cancer in High-Risk First Remission Clin. Cancer Res., May 1, 2008; 14(9): 2740 - 2748. [Abstract] [Full Text] [PDF]

				K. Odunsi, F. Qian, J. Matsuzaki, P. Mhawech-Fauceglia, C. Andrews, E. W. Hoffman, L. Pan, G. Ritter, J. Villella, B. Thomas, et al. Vaccination with an NY-ESO-1 peptide of HLA class I/II specificities induces integrated humoral and T cell responses in ovarian cancer PNAS, July 31, 2007; 104(31): 12837 - 12842. [Abstract] [Full Text] [PDF]

				P. Sabbatini and K. Odunsi Immunologic Approaches to Ovarian Cancer Treatment J. Clin. Oncol., July 10, 2007; 25(20): 2884 - 2893. [Abstract] [Full Text] [PDF]

				M. Garg, D. Chaurasiya, R. Rana, N. Jagadish, D. Kanojia, N. Dudha, N. Kamran, S. Salhan, A. Bhatnagar, S. Suri, et al. Sperm-Associated Antigen 9, a Novel Cancer Testis Antigen, Is a Potential Target for Immunotherapy in Epithelial Ovarian Cancer Clin. Cancer Res., March 1, 2007; 13(5): 1421 - 1428. [Abstract] [Full Text] [PDF]

				E. Jager, J. Karbach, S. Gnjatic, A. Neumann, A. Bender, D. Valmori, M. Ayyoub, E. Ritter, G. Ritter, D. Jager, et al. Recombinant vaccinia/fowlpox NY-ESO-1 vaccines induce both humoral and cellular NY-ESO-1-specific immune responses in cancer patients PNAS, September 26, 2006; 103(39): 14453 - 14458. [Abstract] [Full Text] [PDF]

				Z. Varga, J.-P. Theurillat, V. Filonenko, B. Sasse, B. Odermatt, A. A. Jungbluth, Y.-T. Chen, L. J. Old, A. Knuth, D. Jager, et al. Preferential Nuclear and Cytoplasmic NY-BR-1 Protein Expression in Primary Breast Cancer and Lymph Node Metastases. Clin. Cancer Res., May 1, 2006; 12(9): 2745 - 2751. [Abstract] [Full Text] [PDF]

				A. Erkanli, D. D. Taylor, D. Dean, F. Eksir, D. Egger, J. Geyer, B. H. Nelson, B. Stone, H. A. Fritsche, and R. B.S. Roden Application of Bayesian Modeling of Autologous Antibody Responses against Ovarian Tumor-Associated Antigens to Cancer Detection Cancer Res., February 1, 2006; 66(3): 1792 - 1798. [Abstract] [Full Text] [PDF]

				D. Valmori, F. Qian, M. Ayyoub, C. Renner, A. Merlo, S. Gjnatic, E. Stockert, D. Driscoll, S. Lele, L. J. Old, et al. Expression of Synovial Sarcoma X (SSX) Antigens in Epithelial Ovarian Cancer and Identification of SSX-4 Epitopes Recognized by CD4+ T Cells Clin. Cancer Res., January 15, 2006; 12(2): 398 - 404. [Abstract] [Full Text] [PDF]

				E. Sato, S. H. Olson, J. Ahn, B. Bundy, H. Nishikawa, F. Qian, A. A. Jungbluth, D. Frosina, S. Gnjatic, C. Ambrosone, et al. Intraepithelial CD8+ tumor-infiltrating lymphocytes and a high CD8+/regulatory T cell ratio are associated with favorable prognosis in ovarian cancer PNAS, December 20, 2005; 102(51): 18538 - 18543. [Abstract] [Full Text] [PDF]

				A. O. Gure, R. Chua, B. Williamson, M. Gonen, C. A. Ferrera, S. Gnjatic, G. Ritter, A. J.G. Simpson, Y.-T. Chen, L. J. Old, et al. Cancer-Testis Genes Are Coordinately Expressed and Are Markers of Poor Outcome in Non-Small Cell Lung Cancer Clin. Cancer Res., November 15, 2005; 11(22): 8055 - 8062. [Abstract] [Full Text] [PDF]

				Y. Nagata, T. Hanagiri, M. Takenoyama, T. Fukuyama, M. Mizukami, T. So, Y. Ichiki, M. Sugaya, K. Sugio, and K. Yasumoto Identification of the HLA-Cw*0702-Restricted Tumor-Associated Antigen Recognized by a CTL Clone from a Lung Cancer Patient Clin. Cancer Res., July 15, 2005; 11(14): 5265 - 5272. [Abstract] [Full Text] [PDF]

				E. Purev, D. Cai, E. Miller, R. Swoboda, T. Mayer, A. Klein-Szanto, F. M. Marincola, R. Mick, L. Otvos, W. Wunner, et al. Immune Responses of Breast Cancer Patients to Mutated Epidermal Growth Factor Receptor (EGF-RvIII, {Delta}EGF-R, and de2-7 EGF-R) J. Immunol., November 15, 2004; 173(10): 6472 - 6480. [Abstract] [Full Text] [PDF]

				S. Fujita, H. Wada, A. A. Jungbluth, S. Sato, T. Nakata, Y. Noguchi, Y. Doki, M. Yasui, Y. Sugita, T. Yasuda, et al. NY-ESO-1 Expression and Immunogenicity in Esophageal Cancer Clin. Cancer Res., October 1, 2004; 10(19): 6551 - 6558. [Abstract] [Full Text] [PDF]